Trial · NCT00516321
Results by group524
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 524
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Sustained Virologic Response (SVR) in the Double-blind (DB) Antiviral Treatment Phase | Placebo+Antiviral Therapy: DB Phase | 33 | participants | ||
| Number of Participants With Sustained Virologic Response (SVR) in the Double-blind (DB) Antiviral Treatment Phase | Eltrombopag+Antiviral Therapy: DB Phase | 104 | participants | ||
Number of Participants Whose Platelet Count Increased From a Baseline Count of <75 Gi/L to a Count Greater Than or Equal to (>=) 90 Giga (10^9) Cells Per Liter (Gi/L) During the Open-label (OL) Pre-Antiviral Treatment Phase | Eltrombopag: OL Phase | 691 | participants | ||
| Number of Participants Receiving the Indicated Doses of Eltrombopag in the OL Phase Who Initiated Antiviral Therapy (Peginterferon Alfa-2a and Ribavirin) in the DB Phase | Eltrombopag: OL Phase | 25 mg | 451 | participants | |
| Number of Participants Receiving the Indicated Doses of Eltrombopag in the OL Phase Who Initiated Antiviral Therapy (Peginterferon Alfa-2a and Ribavirin) in the DB Phase | Eltrombopag: OL Phase | 50 mg | 176 | participants | |
| Number of Participants Receiving the Indicated Doses of Eltrombopag in the OL Phase Who Initiated Antiviral Therapy (Peginterferon Alfa-2a and Ribavirin) in the DB Phase | Eltrombopag: OL Phase | 75 mg | 39 | participants | |
| Number of Participants Receiving the Indicated Doses of Eltrombopag in the OL Phase Who Initiated Antiviral Therapy (Peginterferon Alfa-2a and Ribavirin) in the DB Phase | Eltrombopag: OL Phase | 100 mg | 14 | participants | |
| Median Platelet Count at the Indicated Time Points During the OL Phase | Eltrombopag: OL Phase | Baseline, n=712 | 59.00 | Full Range 3.00 to 98.34 | Gi/L |
| Median Platelet Count at the Indicated Time Points During the OL Phase | Eltrombopag: OL Phase | Day 1, n=620 | 59.00 | Full Range 5.00 to 108.00 | Gi/L |
| Median Platelet Count at the Indicated Time Points During the OL Phase | Eltrombopag: OL Phase | Week 1, n=703 | 77.00 | Full Range 7.00 to 226.00 | Gi/L |
| Median Platelet Count at the Indicated Time Points During the OL Phase | Eltrombopag: OL Phase | Week 2, n=426 | 89.00 | Full Range 11.00 to 389.58 | Gi/L |
| Median Platelet Count at the Indicated Time Points During the OL Phase | Eltrombopag: OL Phase | Week 3, n=179 | 83.00 | Full Range 11.00 to 335.00 | Gi/L |
| Median Platelet Count at the Indicated Time Points During the OL Phase | Eltrombopag: OL Phase | Week 4, n=98 | 83.00 | Full Range 12.00 to 310.00 | Gi/L |
| Median Platelet Count at the Indicated Time Points During the OL Phase | Eltrombopag: OL Phase | Week 5, n=56 | 77.00 | Full Range 16.00 to 379.00 | Gi/L |
| Median Platelet Count at the Indicated Time Points During the OL Phase | Eltrombopag: OL Phase | Week 6, n=35 | 79.00 | Full Range 24.00 to 436.00 | Gi/L |
| Median Platelet Count at the Indicated Time Points During the OL Phase | Eltrombopag: OL Phase | Week 7, n=29 | 77.00 | Full Range 30.00 to 187.90 | Gi/L |
| Median Platelet Count at the Indicated Time Points During the OL Phase | Eltrombopag: OL Phase | Week 8, n=18 | 83.00 | Full Range 37.00 to 135.00 | Gi/L |
| Median Platelet Count at the Indicated Time Points During the OL Phase | Eltrombopag: OL Phase | Week 9, n=7 | 70.00 | Full Range 38.00 to 113.00 | Gi/L |
| Median Platelet Count at the Indicated Time Points During the OL Phase | Eltrombopag: OL Phase | Antiviral Baseline, n=48 | 130.00 | Full Range 90.00 to 291.00 | Gi/L |
| Median Platelet Count at the Indicated Time Points During the OL Phase | Eltrombopag: OL Phase | End of Treatment/Withdrawal, n=18 | 63.00 | Full Range 6.00 to 331.97 | Gi/L |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00516321/results